BBOT publishes preclinical data on panKRAS inhibitor BBO-11818 Mar 6, 2026 10:08AM
BridgeBio Oncology Therapeutics (BBOT) Reiterated at Buy by Stifel After Q4 Results Mar 6, 2026 07:32AM
Stifel Starts BridgeBio Oncology Therapeutics, In (BBOT) at Buy Feb 10, 2026 04:13PM
Raymond James Starts BridgeBio Oncology Therapeutics, In (BBOT) at Outperform Jan 9, 2026 06:05AM
BridgeBio Oncology Therapeutics, In (BBOT) PT Raised to $32 at Leerink Partners Jan 8, 2026 10:21AM


Jan 7, 2026 12:28PM Oppenheimer on BridgeBio Oncology Therapeutics, In (BBOT): 'We think the lack of idiosyncratic toxicity is particularly notable for BBO-10203'
Jan 7, 2026 12:11PM Erasca, Inc (ERAS) Pulls Back from 20+pct Jump, Stifel: 'Today's Strength Driven by Competitor Readthrough'
Jan 7, 2026 11:30AM Morgan Stanley on BridgeBio Oncology Therapeutics, In (BBOT): 'Strong efficacy and tolerability for BBO-8520'
Jan 7, 2026 07:01AM BBOT reports clinical data for three cancer drug candidates
Dec 5, 2025 12:26AM Morgan Stanley Starts BridgeBio Oncology Therapeutics, In (BBOT) at Overweight
Sep 17, 2025 06:10AM Leerink Partners Starts BridgeBio Oncology Therapeutics, In (BBOT) at Outperform
Sep 15, 2025 06:41AM H.C. Wainwright Starts BridgeBio Oncology Therapeutics, In (BBOT) at Buy
Sep 4, 2025 06:02AM Oppenheimer Starts BridgeBio Oncology Therapeutics, In (BBOT) at Outperform
Aug 29, 2025 04:12PM BridgeBio Oncology Therapeutics (BBOT) Files for 63.05M Share Offering by Selling Stockholders
Aug 18, 2025 06:49AM Wedbush Reiterates Outperform Rating on BridgeBio Oncology Therapeutics, In (BBOT)
Aug 13, 2025 06:48AM Cantor Fitzgerald Starts BridgeBio Oncology Therapeutics, In (BBOT) at Overweight
Aug 11, 2025 04:30PM BBOT begins trading on Nasdaq after $382M SPAC merger completion